VPC
Vestal Point Capital Portfolio holdings
AUM
$1.9B
1-Year Return
12.28%
This Quarter Return
-16.95%
1 Year Return
-12.28%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$1.4B
AUM Growth
-$286M
(-17%)
Cap. Flow
-$95.2M
Cap. Flow
% of AUM
-6.8%
Top 10 Holdings %
Top 10 Hldgs %
51.45%
Holding
86
New
13
Increased
27
Reduced
13
Closed
23
Top Buys
| 1 |
Arcellx
ACLX
|
+$125M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
+$50.3M |
| 3 |
Scholar Rock
SRRK
|
+$41.8M |
| 4 |
Vera Therapeutics
VERA
|
+$34.2M |
| 5 |
Nuvalent
NUVL
|
+$33.7M |
Top Sells
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$120M |
| 2 |
Merck
MRK
|
+$79.6M |
| 3 |
Ascendis Pharma
ASND
|
+$57.6M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$56.5M |
| 5 |
Soleno Therapeutics
SLNO
|
+$47.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Liquidia Corp
LQDA
$2.39B
| $18.1M | 1.29% |
1,227,403
-532,597
| -30% | -$7.86M |
|
27
Cogent Biosciences
COGT
$1.79B
| $18M | 1.28% |
+3,000,000
| New | +$18M |
|
28
Establishment Labs
ESTA
$1.14B
| $17.7M | 1.26% |
433,193
+133,193
| +44% | +$5.43M |
|
|
VRNA
29
Verona Pharma
VRNA
$9.19B
| $17M | 1.21% |
267,627
-227,373
| -46% | -$14.4M |
|
30
Perrigo
PRGO
$3.07B
| $16.5M | 1.18% |
587,649
+212,649
| +57% | +$5.96M |
|
31
GE HealthCare
GEHC
$35.9B
| $16.5M | 1.18% |
+204,130
| New | +$16.5M |
|
|
NYXH
32
Nyxoah
NYXH
$214M
| $16.2M | 1.16% |
2,318,954
-605,262
| -21% | -$4.22M |
|
33
Globus Medical
GMED
$7.98B
| $14.6M | 1.05% |
200,000
-125,000
| -38% | -$9.15M |
|
34
Nurix Therapeutics
NRIX
$703M
| $13.4M | 0.95% |
1,125,552
+640,552
| +132% | +$7.61M |
|
35
Sarepta Therapeutics
SRPT
$1.85B
| $12.8M | 0.91% |
200,000
-50,000
| -20% | -$3.19M |
|
36
Bruker
BRKR
$4.73B
| $12.5M | 0.89% |
+300,000
| New | +$12.5M |
|
37
Cidara Therapeutics
CDTX
$1.6B
| $10.9M | 0.78% |
+504,542
| New | +$10.9M |
|
38
Black Diamond Therapeutics
BDTX
$185M
| $8.68M | 0.62% |
5,600,000
| – | – |
|
39
MoonLake Immunotherapeutics
MLTX
$3.62B
| $7.81M | 0.56% |
+200,000
| New | +$7.81M |
|
40
Solid Biosciences
SLDB
$389M
| $6.49M | 0.46% |
1,753,558
-1,096,442
| -38% | -$4.06M |
|
41
Immunovant
IMVT
$2.86B
| $5.98M | 0.43% |
350,000
+305,000
| +678% | +$5.21M |
|
42
Zymeworks
ZYME
$1.15B
| $5.96M | 0.43% |
500,000
+315,000
| +170% | +$3.75M |
|
43
Applied Therapeutics
APLT
$63.4M
| $5.62M | 0.4% |
11,500,000
| – | – |
|
|
ITOS
44
DELISTED
iTeos Therapeutics
ITOS
| $5.37M | 0.38% |
900,000
| – | – |
|
45
Galapagos
GLPG
$2.15B
| $5.02M | 0.36% |
200,000
+20,000
| +11% | +$502K |
|
46
Voyager Therapeutics
VYGR
$222M
| $4.22M | 0.3% |
1,249,418
+19,418
| +2% | +$65.6K |
|
47
Lexeo Therapeutics
LXEO
$280M
| $3.94M | 0.28% |
1,136,249
-63,751
| -5% | -$221K |
|
48
Kiniksa Pharmaceuticals
KNSA
$2.73B
| $3.77M | 0.27% |
+169,864
| New | +$3.77M |
|
49
Celldex Therapeutics
CLDX
$1.61B
| $3.61M | 0.26% |
198,646
-106,354
| -35% | -$1.93M |
|
|
OKUR
50
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$34.8M
| $2.73M | 0.2% |
635,000
| – | – |
|